Amy Peterson
2021 - CytomX Therapeutics
In 2021, Amy Peterson earned a total compensation of $2.3M as President, Chief Operating Officer at CytomX Therapeutics, a 150% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $266,810 |
|---|---|
| Option Awards | $1,246,265 |
| Salary | $520,605 |
| Stock Awards | $213,600 |
| Other | $5,000 |
| Total | $2,252,280 |
Peterson received $1.2M in option awards, accounting for 55% of the total pay in 2021.
Peterson also received $266.8K in non-equity incentive plan, $520.6K in salary, $213.6K in stock awards and $5K in other compensation.
Rankings
In 2021, Amy Peterson's compensation ranked 5,579th out of 12,405 executives tracked by ExecPay. In other words, Peterson earned more than 55.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,579 out of 12,405 | 55th |
Division Manufacturing | 2,360 out of 5,494 | 57th |
Major group Chemicals And Allied Products | 1,024 out of 2,369 | 57th |
Industry group Drugs | 913 out of 2,090 | 56th |
Industry Pharmaceutical Preparations | 658 out of 1,537 | 57th |
Source: SEC filing on April 27, 2022.
Peterson's colleagues
We found five more compensation records of executives who worked with Amy Peterson at CytomX Therapeutics in 2021.
2021
Sean McCarthy
CytomX Therapeutics
Chief Executive Officer
2021
Jeff Landau
CytomX Therapeutics
Senior Vice President and Chief Business Officer
2021
Alison Hannah
CytomX Therapeutics
Chief Medical Officer
2021
Lloyd Rowland
CytomX Therapeutics
General Counsel
2021
Carlos Campoy
CytomX Therapeutics
Chief Financial Officer
News
CytomX Therapeutics CEO Sean McCarthy's 2022 pay falls 31% to $3M
April 27, 2023
CytomX Therapeutics CEO Sean McCarthy's 2021 pay jumps 52% to $4.3M
April 27, 2022
BeiGene, Ltd. CEO John Oyler's 2019 pay falls 55% to $13M
April 28, 2020
BeiGene, Ltd. CEO John Oyler's 2018 pay jumps 171% to $28M
April 29, 2019